A detailed history of Keystone Financial Group transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Keystone Financial Group holds 14,000 shares of EDIT stock, worth $37,240. This represents 0.02% of its overall portfolio holdings.

Number of Shares
14,000
Holding current value
$37,240
% of portfolio
0.02%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$3.39 - $5.96 $47,460 - $83,440
14,000 New
14,000 $47,000
Q2 2022

Aug 05, 2022

BUY
$9.99 - $21.35 $139,860 - $298,900
14,000 New
14,000 $166,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $183M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Keystone Financial Group Portfolio

Follow Keystone Financial Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Keystone Financial Group, based on Form 13F filings with the SEC.

News

Stay updated on Keystone Financial Group with notifications on news.